Get 20% Off Journals at

Sleep disturbances in patients with lung cancer in Turkey.

Tuberk Toraks 2018 Dec;66(4):297-303

Department of Chest Diseases, Faculty of Medicine, Bolu Abant Izzet Baysal University, Bolu, Turkey.

Introduction: Sleep quality is known to be associated with the distressing symptoms of cancer. The purpose of this study was to analyze the impact of cancer symptoms on insomnia and the prevalence of sleep-related problems reported by the patients with lung cancer in Turkey.

Materials And Methods: Assesment of Palliative Care in Lung Cancer in Turkey (ASPECT) study, a prospective multicenter study conducted in Turkey with the participation of 26 centers and included all patients with lung cancer, was re-evaluated in terms of sleep problems, insomnia and possible association with the cancer symptoms. Demographic characteristics of patients and information about disease were recorded for each patient by physicians via face-to-face interviews, and using hospital records. Patients who have difficulty initiating or maintaining sleep (DIMS) is associated with daytime sleepiness/fatigue were diagnosed as having insomnia. Daytime sleepiness, fatigue and lung cancer symptoms were recorded and graded using the Edmonton Symptom Assessment Scale.

Result: Among 1245 cases, 48.4% reported DIMS, 60.8% reported daytime sleepiness and 82.1% reported fatigue. The prevalence of insomnia was 44.7%. Female gender, patients with stage 3-4 disease, patients with metastases, with comorbidities, and with weight loss > 5 kg had higher rates of insomnia. Also, patients with insomnia had significantly higher rates of pain, nausea, dyspnea, and anxiety. Multivariate logistic regression analysis showed that patients with moderate to severe pain and dyspnea and severe anxiety had 2-3 times higher rates of insomnia.

Conclusions: In conclusion, our results showed a clear association between sleep disturbances and cancer symptoms. Because of that, adequate symptom control is essential to maintain sleep quality in patients with lung cancer.

Download full-text PDF

Source Listing
December 2018
Save 15% Survey

Similar Publications

The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis.

Neuro Oncol 2021 Feb 25. Epub 2021 Feb 25.

Computational Neuroscience Outcomes Center (CNOC), Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States.

Background: Immune checkpoint inhibitors (ICI) have been a breakthrough for selected cancer patients, including those with brain metastases (BMs). Likewise, steroids have been an integral component of symptomatic management of BM patients. However, clinical evidence on the interaction between ICI and steroids in BM patients is conflicting and has not adequately been summarized thus far. Read More

View Article and Full-Text PDF
February 2021

The Role of Immune-Related Adverse Events in Prognosis and Efficacy Prediction for Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy: A Retrospective Clinical Analysis.

Oncology 2021 Feb 25:1-9. Epub 2021 Feb 25.

First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.

Purpose: The development of immune-related adverse events (irAEs) in patients undergoing immunotherapy has been reported to be a favorable prognostic factor in several studies. We aimed to examine the correlation between irAEs and prognosis in patients with non-small cell lung cancer (NSCLC) and further reveal the patient characteristics associated with response to immunotherapy among treatment responders who developed irAEs.

Methods: We retrospectively enrolled 80 patients with NSCLC who received immunotherapy at Shinshu University Hospital between February 2016 and February 2020. Read More

View Article and Full-Text PDF
February 2021

EZH2-mediated epigenetic suppression of SH3BGRL potently inhibits lung cancer progression.

Biochem Biophys Res Commun 2021 Feb 22;548:53-59. Epub 2021 Feb 22.

Department of Oncology, The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China. Electronic address:

Lung cancer is the leading cause of cancer-related deaths worldwide. Lung cancer stem cells (CSCs) are a small population of cancer cells with self-renewal, therapeutic resistance, and tumor relapse capability. Yet the molecular mechanisms underlying lung CSCs self-renewal remain largely unknown. Read More

View Article and Full-Text PDF
February 2021

Structural basis of the p53 DNA binding domain and PUMA complex.

Biochem Biophys Res Commun 2021 Feb 22;548:39-46. Epub 2021 Feb 22.

Department of Molecular Biology, College of Natural Sciences, Pusan National University, 2Busandaehak-ro 63beon-gil, Geumjeong-gu, Busan, 46241, Republic of Korea. Electronic address:

PUMA (p53-upregulated modulator of apoptosis) is localized in mitochondria and a direct target in p53-mediated apoptosis. p53 elicits mitochondrial apoptosis via transcription-dependent and independent mechanisms. p53 is known to induce apoptosis via the transcriptional induction of PUMA, which encodes proapoptotic BH3-only members of the Bcl-2 protein family. Read More

View Article and Full-Text PDF
February 2021

Unusual case of cavitary lung metastasis of esophageal cancer: A case report.

Int J Surg Case Rep 2021 Feb 18;80:105662. Epub 2021 Feb 18.

Department of Thoracic Surgery, Ishikawa Prefectural Central Hospital, 2-1 Kuratsukihigashi, Kanazawa, Ishikawa, 9208530, Japan. Electronic address:

Introduction And Importance: Cavitary lung metastases are rare. We experienced lung metastasis of esophageal cancer with a cavity, which is extremely rare.

Case Presentation: A 69-year-old female diagnosed with thoracic esophageal cancer underwent radical esophagectomy. Read More

View Article and Full-Text PDF
February 2021